Navigation Links
Cephalon Reports Record Earnings and Raises 2010 Guidance
Date:10/28/2010

$325-$345 million.  Full year R&D and SG&A guidance is $430-$450 million and $910-$930 million, respectively.  Adjusted net income guidance is increased to $617-$632 million and basic adjusted income per common share guidance is increased to $8.20-$8.40, assuming 75.2 million basic shares outstanding.

Cephalon is introducing full year 2011 sales guidance of $2.96-$3.04 billion.  This includes CNS franchise sales of $1.39-$1.43 billion, pain franchise sales of $540-$570 million, oncology franchise sales of $570-$600 million, and other product sales of $420-$450 million. R&D and SG&A guidance for 2011 are $505-$525 million and $970 million-$1 billion, respectively.

The company also is introducing adjusted net income guidance for full year 2011 of $652-$668 million.  Cephalon is introducing 2011 adjusted net income per common share guidance of $8.45-$8.65, assuming 77.2 million basic shares outstanding.  

Basic adjusted income per common share guidance for both the full-year 2010 and full-year 2011 is reconciled below and is subject to the assumptions set forth therein. References in this press release to basic income per common share, basic adjusted income per common share, basic adjusted income per common share guidance, adjusted net income, adjusted net income guidance, adjusted net income per common share, adjusted net income per common share guidance refer to those metrics on an "attributable to Cephalon" basis and do not include any income or losses attributable to noncontrolling interests.

The Cephalon management will discuss the company's third quarter 2010 performance in a conference call with investors beginning at 5:00 p.m. U.S. EDT today.  To participate in the conference call, dial +913-312-0678 and refer to conference code 4886405. Investors can listen to the call live by logging on to the company's website at www.cephalon.com and clicking on "
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
2. Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
3. Cephalon Completes Acquisition of Arana Therapeutics
4. Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Prices 5 Million Shares of Common Stock and $435 Million in 2.50% Convertible Senior Subordinated Notes in Public Offerings
7. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
8. Cephalons New Product Launches Pace Record 2008 Sales
9. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
10. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
11. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... (PRWEB) July 31, 2014 North Shore Towers, ... City, partnered with GI Energy, one of the nation’s leading ... $13 million upgrade of its 43-year-old CHP system. The original ... in an effort to extend the life of the plant, ... and associated electrical and heat recovery equipment, while maintaining continuous ...
(Date:7/31/2014)... Senomyx , Inc. (NASDAQ: SNMX ... technologies to discover, develop, and commercialize novel flavor ... industries, today reported financial results for the second ... with $33.6 million in cash and highly liquid ... Senomyx achieved another important milestone with the regulatory ...
(Date:7/31/2014)... Rancho BioSciences , the scientific ... Array Suite with tranSMART . Scientists that ... send data in tranSMART to Array Suite for further ... tranSMART including the new 1.2 release. Array Suite ... for the analysis of high dimensional quantification data, including ...
(Date:7/31/2014)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ... clinical grade hypothermic storage and cryopreservation ... for cells and tissues, today announced today that ... released on Thursday, August 7, 2014, and that the ... at 4:30 p.m. ET that afternoon. Management will provide ...
Breaking Biology Technology:North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3BioLife Solutions to Report Financial Results for Second Quarter 2014 and Provide Business Update on August 7, 2014 2
... County Representatives Unveil State-of-the-Art Facility ... ... Officials from Novavax,Inc. (Nasdaq: NVAX ), the State ... new state-of-the-art vaccine production,facility at the company,s headquarters in Rockville, ...
... Total Revenues of $62.0 Million, Up 55 Percent over First Quarter ... 2007, - First ... Before Non-Cash Charges of $1.13 per Basic Share, ... per Diluted Share, SILVER SPRING, Md., May 1 United Therapeutics,Corporation (Nasdaq: UTHR ) ...
... Strategic Transactions Increase EUSA,s Focus on Late-Stage and Marketed ... ... Products, DOYLESTOWN, Pennsylvania and OXFORD, England, May 1 ,EUSA ... pain control and critical care, today announced that,it has divested ...
Cached Biology Technology:Novavax Opens Its First U.S. Vaccine Plant 2Novavax Opens Its First U.S. Vaccine Plant 3Novavax Opens Its First U.S. Vaccine Plant 4United Therapeutics Reports First Quarter 2008 Financial Results 2United Therapeutics Reports First Quarter 2008 Financial Results 3United Therapeutics Reports First Quarter 2008 Financial Results 4United Therapeutics Reports First Quarter 2008 Financial Results 5United Therapeutics Reports First Quarter 2008 Financial Results 6United Therapeutics Reports First Quarter 2008 Financial Results 7EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product 2EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product 3
(Date:7/30/2014)... paving the way for a breakthrough that may ... exposed to poisonous chemicalsparticularly those in pesticides and ... current issue of the journal ChemBioChem ... compounds commonly used in pesticides and warfare agents. ... of Engineering Associate Professor of Chemical and Biological ...
(Date:7/30/2014)... studying the potential effects of climate change on ... on the wrong factors, according to a new ... Conservation Society, University of Queensland, and other organizations. ... science is missing the point when it comes ... of climate change scientists focus on the "direct" ...
(Date:7/30/2014)... pleased to announce its new relationship with the International ... CINP will partner to publish International Journal of ... journal. , Alan Frazer, Editor-in-Chief of IJNP ... of OUP will further facilitate the goal for the ... leading journals within neuropsychopharmacology. The conversion of the ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2OUP to partner with the International College of Neuropsychopharmacology 2
... a research team from the National Institute of Standards ... has shown how to detect and monitor the tiny ... of an atomic force microscope probe, and in so ... of the instruments measurements under ambient conditions. Their recently ...
... have learned to manipulate the proportion of females and ... mapped the entire genome of a bacterium that infects ... published in PNAS, reveal extremely high frequencies of gene ... it is hoped that it will be possible to ...
... DC, March 25, 2009 - Critically endangered hawksbill turtles ... the Dominican Republic after a powerful government campaign cracked ... 99 percent of these souvenirs have been withdrawn or ... A 2006 survey carried out by TRAFFIC found ...
Cached Biology News:Making a point: Picoscale stability in a room-temperature AFM 2Gene exchange common among sex-manipulating bacteria 2Turtles no longer turned into souvenirs 2
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
Src cDNA Expression Kit (wild type)...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Biology Products: